Home › Schizophrenia › Illinois
Pag-aaral pangklinika para sa Schizophrenia sa Illinois
25 pag-aaral para sa Schizophrenia ang naghahanap ng mga kalahok sa mga site sa Illinois.
Mga Lungsod sa Illinois
Opisyal na teksto ng pag-aaral (English)
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07686263A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
Nagre-recruitPhase 1
Edad 18 hanggang 55 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07615426NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
Nagre-recruitPhase 3
Edad 5 hanggang 17 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06229210A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
Nagre-recruitPhase 2
Edad 18 hanggang 55 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Nagre-recruitPhase 3
Edad 5 hanggang 17 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
Nagre-recruitPhase 3
Edad 13 hanggang 17 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
Nagre-recruitPhase 1
Edad 18 hanggang 55 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07459647Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07101094Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
Nagre-recruitPhase 3
Edad 10 hanggang 17 · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 40 · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
Nagre-recruitPhase 2
Edad 18 hanggang 55 · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
Nagre-recruitPhase 4
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
Nagre-recruitPhase 4
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update May 11, 2026 · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 40 · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Mar 6, 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ene 12, 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
Nagre-recruitPhase 2
Edad 21 hanggang 55 · Lahat ng kasarian · Na-update Dis 26, 2025 · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Dis 19, 2024 · NCT05184335Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.